Sponsor name | Trials on EUCTR | Trials due to report results | % Reported | Trials with inconsistent data | Major? |
---|---|---|---|---|---|
Novartis | 1414 | 754 | 100.0% | 369 | major |
GlaxoSmithKline | 1129 | 498 | 99.8% | 488 | major |
Pfizer | 843 | 257 | 98.4% | 444 | major |
Merck Sharp & Dohme (MSD) | 779 | 432 | 100.0% | 178 | major |
Roche | 705 | 191 | 92.1% | 288 | major |
Sanofi S.A. | 679 | 179 | 99.4% | 392 | major |
Astrazeneca | 651 | 240 | 96.2% | 200 | major |
Johnson & Johnson | 506 | 175 | 98.9% | 205 | major |
Eli Lilly | 444 | 152 | 99.3% | 166 | major |
Medical University of Vienna | 400 | 217 | 24.4% | 36 | major |
Bristol-Myers Squibb | 373 | 87 | 96.6% | 150 | major |
Boehringer Ingelheim | 372 | 148 | 100.0% | 154 | major |
Bayer | 316 | 206 | 100.0% | 55 | major |
Hospitals of Paris (AP-HP) | 296 | 24 | 4.2% | 44 | major |
Amgen Inc | 285 | 90 | 96.7% | 121 | major |
Gilead Sciences Inc | 242 | 100 | 99.0% | 97 | major |
KU Leuven | 242 | 27 | 66.7% | 28 | major |
Novo Nordisk | 239 | 90 | 100.0% | 93 | major |
Abbvie | 235 | 93 | 97.8% | 40 | major |
Rigshospitalet | 230 | 87 | 12.6% | 49 | major |
Radboud University | 229 | 21 | 19.0% | 33 | major |
Karolinska Institutet | 221 | 26 | 11.5% | 23 | major |
UCB | 212 | 63 | 93.7% | 101 | major |
Takeda | 208 | 87 | 98.9% | 62 | major |
No Sponsor Name Given | 208 | 42 | 42.9% | 33 | major |
Erasmus University | 204 | 4 | 25.0% | 28 | major |
Charité-Universitätsmedizin Berlin | 196 | 74 | 51.4% | 32 | major |
University of Amsterdam | 191 | 13 | 0.0% | 29 | major |
Aarhus University | 185 | 75 | 29.3% | 22 | major |
VU University Medical Centre | 172 | 15 | 0.0% | 17 | major |
Merck KGaA | 169 | 46 | 97.8% | 75 | major |
University College London | 162 | 80 | 95.0% | 7 | major |
Leiden University | 158 | 9 | 11.1% | 13 | major |
Agostino Gemelli University Polyclinic | 153 | 11 | 0.0% | 104 | major |
Astellas | 152 | 45 | 100.0% | 75 | major |
Utrecht University | 152 | 15 | 20.0% | 40 | major |
University of Groningen | 150 | 4 | 0.0% | 9 | major |
University of Oxford | 146 | 77 | 81.8% | 4 | major |
Imperial College London | 144 | 96 | 95.8% | 6 | major |
Servier Laboratories | 144 | 67 | 100.0% | 50 | major |
Allergan | 142 | 72 | 95.8% | 38 | major |
Novartis Vaccines | 141 | 56 | 100.0% | 77 | major |
Ghent University | 141 | 39 | 20.5% | 46 | major |
Celgene | 135 | 42 | 92.9% | 36 | major |
IRCCS Ospedale San Raffaele | 126 | 7 | 28.6% | 49 | major |
AOU di Bologna, Policlinico S.Orsola-Malpighi | 126 | 1 | 0.0% | 33 | major |
Eisai Inc. | 125 | 37 | 97.3% | 61 | major |
Medical University of Graz | 123 | 64 | 32.8% | 8 | major |
Biogen | 123 | 58 | 96.6% | 38 | major |
Helsinki University | 119 | 18 | 22.2% | 9 | major |
Pierre Fabre S.A. | 118 | 67 | 98.5% | 22 | major |
University of Birmingham | 116 | 50 | 90.0% | 5 | major |
Shire | 110 | 33 | 100.0% | 48 | major |
Abbott | 109 | 73 | 95.9% | 31 | major |
Odense University Hospital | 108 | 44 | 25.0% | 21 | major |
University of Oslo | 107 | 6 | 16.7% | 9 | major |
King’s College London | 106 | 65 | 98.5% | 2 | major |
Chiesi Farmaceutici S.p.A | 105 | 54 | 100.0% | 31 | major |
European Organisation for the Research and Treatment of Cancer (EORTC) | 105 | 27 | 66.7% | 32 | major |
Hospices Civils de Lyon | 100 | 13 | 0.0% | 10 | major |
Vertex Pharmaceuticals, Inc. | 99 | 41 | 100.0% | 36 | major |
Université libre de Bruxelles | 96 | 6 | 0.0% | 11 | major |
Actelion Pharmaceuticals Ltd | 95 | 32 | 100.0% | 37 | major |
Teva | 94 | 46 | 91.3% | 36 | major |
Herlev and Gentofte Hospital | 89 | 37 | 54.1% | 15 | major |
Ipsen | 88 | 38 | 100.0% | 33 | major |
H. Lundbeck A/S | 86 | 42 | 97.6% | 30 | major |
CSL Behring | 83 | 34 | 100.0% | 37 | major |
Antoni van Leeuwenhoek Hospital | 83 | 2 | 0.0% | 8 | major |
Guy's and St Thomas' NHS Foundation Trust | 82 | 46 | 100.0% | 2 | major |
University of Munich (Ludwig-Maximilians) | 79 | 37 | 13.5% | 5 | major |
Unicancer | 79 | 5 | 0.0% | 3 | major |
Fundació Clínic per a la Recerca Biomèdica | 77 | 5 | 0.0% | 29 | major |
Genentech | 76 | 37 | 100.0% | 18 | major |
Alcon | 76 | 36 | 100.0% | 39 | major |
University of Dundee | 74 | 68 | 97.1% | 1 | major |
Otsuka | 74 | 38 | 92.1% | 24 | major |
Daiichi Sankyo | 74 | 28 | 100.0% | 29 | major |
Maastricht University | 74 | 4 | 0.0% | 14 | major |
Gothenburg University | 73 | 7 | 14.3% | 11 | major |
National Cancer Institute Italy | 73 | 3 | 0.0% | 19 | major |
University of Leeds | 72 | 50 | 100.0% | 1 | major |
NHS Greater Glasgow and Clyde | 70 | 36 | 72.2% | 4 | major |
Innsbruck Medical University | 70 | 26 | 65.4% | 7 | major |
Regeneron Pharmaceuticals Inc. | 70 | 14 | 100.0% | 20 | major |
The Newcastle upon Tyne Hospitals NHS Foundation Trust | 69 | 53 | 90.6% | 1 | major |
Menarini Group | 69 | 44 | 93.2% | 11 | major |
Alexion Pharmaceuticals, Inc | 69 | 20 | 80.0% | 21 | major |
University of Cologne | 68 | 29 | 65.5% | 7 | major |
Technical University of Munich | 67 | 32 | 81.2% | 11 | major |
CHU de Toulouse | 67 | 12 | 0.0% | 9 | major |
Incyte Corporation | 66 | 14 | 85.7% | 6 | major |
ACCORD (University of Edinburgh & NHS Lothian) | 65 | 39 | 76.9% | 3 | major |
Vrije Universiteit Brussel | 64 | 4 | 25.0% | 9 | major |
University of Nottingham | 63 | 54 | 94.4% | 4 | major |
Baxter | 63 | 47 | 93.6% | 9 | major |
Vall d'Hebron University Hospital | 63 | 3 | 0.0% | 12 | major |
Manchester University NHS Foundation Trust | 62 | 52 | 100.0% | 0 | major |
Queen Mary University of London | 62 | 36 | 94.4% | 3 | major |
Galderma R&D | 62 | 34 | 97.1% | 14 | major |
University Hospital Tübingen | 61 | 17 | 11.8% | 8 | major |
CHU Clermont-Ferrand | 61 | 9 | 0.0% | 7 | major |
Heidelberg University Hospital | 60 | 26 | 65.4% | 5 | major |
Hospital de la Santa Creu i Sant Pau | 60 | 10 | 0.0% | 13 | major |
Almirall S.A. | 59 | 39 | 100.0% | 10 | major |
LEO Pharma A/S | 59 | 32 | 96.9% | 14 | major |
The Royal Marsden NHS Foundation Trust | 59 | 25 | 80.0% | 2 | major |
HOVON Foundation | 59 | 2 | 0.0% | 3 | major |
University Erlangen-Nuremberg | 58 | 22 | 59.1% | 4 | major |
European Institute of Oncology | 58 | 1 | 0.0% | 16 | major |
Ferring Pharmaceuticals | 57 | 29 | 96.6% | 20 | major |
Cliniques Universitaires Saint-Luc | 57 | 4 | 0.0% | 12 | major |
University Hospitals of Leicester NHS Trust | 56 | 45 | 95.6% | 5 | major |
Bispebjerg Hospital | 56 | 31 | 25.8% | 9 | major |
University of Turku | 56 | 11 | 18.2% | 2 | major |
Belfast Health and Social Care Trust | 55 | 42 | 81.0% | 1 | major |
Hannover Medical School | 54 | 28 | 21.4% | 13 | major |
Mundipharma | 53 | 30 | 90.0% | 15 | major |
King's College Hospital NHS Foundation Trust | 52 | 36 | 91.7% | 1 | major |
Hvidovre Hospital | 52 | 19 | 26.3% | 12 | major |
Skåne University Hospital | 52 | 10 | 20.0% | 4 | major |
CHU de Bordeaux | 52 | 7 | 0.0% | 10 | major |
Barts Health NHS Trust | 51 | 42 | 95.2% | 4 | major |
Cambridge University Hospitals NHS Foundation Trust | 51 | 36 | 91.7% | 5 | major |
BioMarin Pharmaceutical Inc | 51 | 19 | 78.9% | 12 | major |
University Hospital Southampton NHS Foundation Trust | 50 | 19 | 21.1% | 2 | major |
University of Hamburg | 50 | 16 | 43.8% | 6 | major |
Policlinico San Matteo | 50 | 4 | 0.0% | 33 | major |